These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 18089876)

  • 21. Hormone replacement therapy and lung cancer risk in Chinese.
    Chen KY; Hsiao CF; Chang GC; Tsai YH; Su WC; Perng RP; Huang MS; Hsiung CA; Chen CJ; Yang PC;
    Cancer; 2007 Oct; 110(8):1768-75. PubMed ID: 17879370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population.
    Huang B; Carloss H; Wyatt SW; Riley E
    Cancer; 2009 Sep; 115(18):4167-75. PubMed ID: 19526591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Estrogen replacement therapy and breast cancer].
    Bakken K; Alsaker E; Eggen AE; Lund E
    Tidsskr Nor Laegeforen; 2005 Feb; 125(3):282-5. PubMed ID: 15702147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone replacement therapy is associated with decreased survival in women with lung cancer.
    Ganti AK; Sahmoun AE; Panwalkar AW; Tendulkar KK; Potti A
    J Clin Oncol; 2006 Jan; 24(1):59-63. PubMed ID: 16314616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer.
    Kawai H; Ishii A; Washiya K; Konno T; Kon H; Yamaya C; Ono I; Ogawa J
    Anticancer Res; 2005; 25(6C):4693-8. PubMed ID: 16334162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
    Tewari M; Pradhan S; Singh U; Shukla HS
    Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.
    Alvarez-Vasquez RB; Axelrod D; Frenkel K; Newman MC; Sepkovic DW; Bradlow HL; Zumoff B
    Horm Metab Res; 2003 Jun; 35(6):358-61. PubMed ID: 12920658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Cancer; 2012 Jan; 118(1):157-63. PubMed ID: 21713768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone replacement therapy and messenger RNA expression of estrogen receptor coregulators after exercise in postmenopausal women.
    Dieli-Conwright CM; Spektor TM; Rice JC; Sattler FR; Schroeder ET
    Med Sci Sports Exerc; 2010 Mar; 42(3):422-9. PubMed ID: 20164697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women.
    Gebhart JB; Rickard DJ; Barrett TJ; Lesnick TG; Webb MJ; Podratz KC; Spelsberg TC
    Am J Obstet Gynecol; 2001 Dec; 185(6):1325-30; discussion 1330-1. PubMed ID: 11744904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormone therapy and estrogen receptor expression in breast cancer.
    Friman EI; Mahlman M; Nilsson B; Skoog L; Löfgren L; Wilking N; Von Schoultz E
    Acta Oncol; 2007; 46(2):194-8. PubMed ID: 17453368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort.
    Rodriguez C; Spencer Feigelson H; Deka A; Patel AV; Jacobs EJ; Thun MJ; Calle EE
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):655-60. PubMed ID: 18349283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogens and epithelial ovarian cancer.
    Cunat S; Hoffmann P; Pujol P
    Gynecol Oncol; 2004 Jul; 94(1):25-32. PubMed ID: 15262115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
    Li CI; Malone KE; Daling JR
    Cancer Causes Control; 2006 Jun; 17(5):695-703. PubMed ID: 16633917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for estrogen receptor-positive breast cancer.
    Hwang ES; Chew T; Shiboski S; Farren G; Benz CC; Wrensch M
    Arch Surg; 2005 Jan; 140(1):58-62. PubMed ID: 15655207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer--a population based cohort study, the HUNT study: are proxy variables friends or faults?
    Hatlen P; Langhammer A; Forsmo S; Carlsen SM; Amundsen T
    Lung Cancer; 2013 Jul; 81(1):39-46. PubMed ID: 23618654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with human small aggressive non small cell lung cancer.
    Tammemagi CM; Freedman MT; Church TR; Oken MM; Hocking WG; Kvale PA; Hu P; Riley TL; Ragard LR; Prorok PC; Berg CD
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2082-9. PubMed ID: 17932357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.